Testing for BRAF V600 variants in tumor tissue of individuals with unresectable or metastatic melanoma, or with resected stage III melanoma may be considered medically necessary to select individuals for treatment with FDA-approved BRAF inhibitors or MEK inhibitors.
Testing for BRAF V600 variants for all other individuals with melanoma is considered investigational.
Testing for BRAF V600E variants in individuals with glioma may be considered medically necessary to select individuals for targeted treatment with dabrafenib in combination with trametinib.
Testing for BRAF V600 variants for all other individuals with glioma to select targeted treatment is considered investigational.
